NCT03405337View on ClinicalTrials.gov

Evaluation of Patient and Physician Reported Reasons for Switching Factor VIII Replacement Therapies

CompletedOBSERVATIONAL

Enrollment

160

Participants

Timeline

Start Date

February 14, 2018

Primary Completion Date

June 13, 2018

Study Completion Date

June 13, 2018

Conditions

Hemophilia A

Interventions

DRUG

FVIII products

Adynovate, Eloctate, Afstyla, Kovaltry

DRUG

Conventional FVIII replacement therapies

Advate, Kogenate FS, Helixate, Novoeight, Nuwiq, Recombinate, Xyntha

Trial Locations (1)

07981

Many Locations, Whippany

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Bayer

INDUSTRY